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Persistent infection with oncogenic human papillomavirus (HPV)
types, of which type 16 is the most prevalent, represents a major
risk factor for the development of cervical carcinoma (Lorincz et
al, 1992; Zur Hausen, 1994). Between 90 and 100% of these
lesions are positive for such high-risk HPV by polymerase chain
reaction (PCR) (Van den Brule et al, 1991; Bosch et al, 1995).
Then infections with high-risk HPV are associated with a relative
risk of between 8 and 11 for the development of squamous intra-
epithelial lesions (SIL) (Koutsky et al, 1992) and only low-grade
SIL containing high-risk HPVs progress to high-grade disease
(Gaarenstroom et al, 1994). Because of this, there is an increasing
interest in using HPV DNA detection, either alone or in addition to
the classic cytological examination, as a method for screening
cervical carcinoma or for triaging women with a cytological diag-
nosis of atypical squamous cells of undetermined significance
(ASCUS) in their cervical smears (Cole, 1993; Richart and
Wright, 1993; Cox et al, 1995). Nevertheless, the low sensitivity
of HPV detection has led some authors to consider that HPV
screening does not appear to be of value for identifying women
with abnormal smears who can be safely followed up with cyto-
logical study alone (Kaufman et al, 1997). Indeed, HPV DNA
testing in cervical scrapes offers a potentially automatic and cheap
diagnostic assay without the sampling problems and subjectivity
of cytology, but such an approach needs a specific, sensitive, reli-
able and easy to perform method.
Three years ago, a commercial HPV detection test, Hybrid
Capture-I (HC-I), was introduced (Farthing et al, 1995; Schiffman
et al, 1995; Sun et al, 1995). HC-I was a non-radioactive, relatively
rapid, liquid hybridization assay designed to detect 14 HPV types
divided into high-risk (types 16, 18, 31, 33, 35, 45, 51, 52 and 56)
and low-risk (types 6, 11, 42, 43 and 44) groups. This test has been
proposed to be used routinely on large series of women to improve
the sensitivity and negative predictive value of cytological
screening for SIL (Sun et al, 1995). The first studies were particu-
larly promising, showing a good agreement with PCR results,
although the method was less sensitive, with a detection of high-
risk HPV DNA in 83–93% in high-grade SIL. These papers, and
the following studies of selected populations, concluded that
screening for cervical intraepithelial neoplasias (CIN) grade 2/3
could be significantly improved by HPV testing with the HC-I
assay. However, in our own experience on a series of 1028 women
attending routine screening, the overall sensitivity in detecting
high-grade SIL with HC-I was only 71.2% and its positive predic-
tive value was 17.8% (Clavel et al, 1998a). Classic cytological
screening remained the most sensitive tool (84%) to detect high-
grade SIL with a positive predictive value of 91.3%. Thus, we
concluded that the crude sensitivity of the HC-I limited its use for
the screening of high-grade lesions on a large scale.
Since this study, a second generation of HC, Hybrid Capture-II
(Digene) (HC-II) using microtiter plates instead of tubes and
detecting four additional viral oncogenic types (types 39, 58, 59
and 68) has been commercialized. The preliminary studies gave
more reliable results with a lower detection limit of 0.2–1 pg HPV
DNA ml–1 (Lorincz, 1996). The aim of the present work was to
study on a large series of unselected women attending routine
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cytological screening, the utility and efficiency of the HPV detec-
tion by the HC-II test to detect histologically proven high-grade
lesions as compared with classic cytological screening, and the
reliability of this test on various well-established high-grade SIL
treated by cone excision.
MATERIALS AND METHODS
A total of 1518 women with a mean age of 37 years (range 15–72
years) were recruited for the study between August 1997 and
December 1998. This population included women who underwent
their triennial routine screeening, women with high risk of sexu-
ally transmitted diseases and women followed in a family planning
clinic, in the Department of Obstetrics and Gynecology of the
CHU of Reims. All women were informed of the aim of the study
and gave their consent. At gynaecological examination, two
samples were taken: first, a cytological smear with an Ayre’s
spatula, then one scrape for the HC-II test with a cytobrush
(Medscan, Uppsala, Sweden). We collected 1647 cervical smears
and scrapes. Moreover, to test the sensitivity and the specificity of
the detection of HPV DNA and of the viral load evaluated by the
HC-II assay, we performed a pilot study with the same approach
on 117 fresh samples of cone biopsies following the discovery of a
high-grade SIL on a previous biopsy, from patients with a mean
age of 37.5 years (range 20–58 years).
Specimens for HPV DNA testing were suspended in 1 ml of
ViraPap/Viratype transport medium (Digene, Silver Spring, MD,
USA) and stored at –20°C until further processing.
Smears were classified according to the Bethesda System for
reporting cervical or vaginal cytological diagnosis. In our protocol
(Figure 1), all the women presenting cytological abnormalities
evocative of cervical lesions were systematically recalled for
colposcopy in the next few weeks, at an interval ranging from 14
to 150 days (mean 90 days) after entry examination. Punch biopsy
specimens were taken from the areas colposcopically suspicious
for CIN. If colposcopy was negative, the woman was recalled 6
months later for a new cytological control and HPV testing. All the
women with smears within normal limits but presenting a HPV
infection were also systematically recalled 6 months later for a
new cytological examination and HPV testing followed by
colposcopy if a lesion and/or a persistent HPV infection was
detected. Punch biopsy specimens were taken from the areas
colposcopically suspicious for CIN. The women with a second
HPV test positive without any detectable lesions were recalled 6
months later for a third control with cytological examination and
HPV testing, and the same indications as above for colposcopy
and biopsy. In total, 114 women had at least two repeated HPV
tests and cytology screens, at an interval ranging from 30 to 450
days (mean 170 days). A total of 165 women had colposcopy and
129 were biopsied. The cytotechnicians and pathologists involved
were not informed about the results of the HPV testing. All biopsy
specimens were examined by two pathologists.
HPV DNA detection was performed by the commercially avail-
able HC-II System (Digene). All scrapes were analysed for the
presence of low-risk HPV types 6, 11, 42, 43 and 44, and high-risk
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.
This enzyme-linked immunosorbent assay is based on a sandwich
hybridization followed by a non-radioactive alkaline phosphatase
reaction with chemoluminescence in microplates (Lorincz, 1996).
The positive threshold of this test is 0.2 pg ml–1 (1000 copies of
HPV per test).
Samples were classified as positive for HPV DNA if the relative
light unit reading obtained from the luminometer was equal or
greater than the mean of positive control values supplied by the
HC-II kit. As some authors have reported that increasing HPV
DNA levels of high-risk HPV types were the principal predictors
of CIN (Cox et al, 1996), we used as proposed, the ratio relative
light units per positive control values to quantify high-risk HPV
DNA in our samples. Moreover, we added other positive controls
such as SiHa cell lines (1–2 copies of HPV type 16 per cell) to
check the reproducibility of the HC-II sensitivity.
Table 1 Prevalence of HPV infections according to age (patients with
double infections were included in high-risk HPV infection)
Age Women High-risk Low-risk Total HPV
<20 85 17 (20.0%) 5 (5.9%) 22 (25.9%)
21–30 411 103 (25.1%) 25 (6.1%) 128 (31.1%)
31–40 484 71 (14.7%) 24 (4.9%) 95 (19.6%)
41–50 369 42 (11.4%) 23 (6.2%) 65 (17.6%)
51–60 128 14 (10.9%) 8 (6.2%) 22 (17.2%)
>60 41 6 (14.6%) 0 6 (14.6%)
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RESULTS
Overall, 400 scrapes out of 1647 (24.3%) were positive for the
detection of HPV by the HC-II test: 296 for high-risk HPV
(18.0%) including 83 double infections and 104 low-risk HPV
(6.3%). These positivities corresponded to 338 out of 1518 women
(22.3%); 85 women (5.6%) were infected by a low-risk HPV and
253 with a high-risk HPV (16.7%).
The data in Table 1 represent the frequency of HPV infection
observed in our 1518 women according to their age. There was a
peak of infection in the third decade (31.1% of women) with a
decrease after 60 years. There was also a significant prevalence of
HPV infection in women who had a history of low- and/or high-
grade lesions in a previous cervical smear or biopsy within the 2
years before examination. Twenty-eight (37.8%) of the 74 women
with a history of lesions were infected with HPV versus
310 (21.5%) of 1444 women without medical history of SIL
(P < 0.001).
HPV detection and cytological and histological
diagnoses
These results are summarized in Table 2. Overall, 1495 (90.8%) of
the 1647 cervical samples included metaplastic and/or endo-
cervical cells. There was a significant increase in the prevalence of
HPV detection, especially high-risk HPV, related to the severity of
the lesions (P < 0.001).
Twenty-five women had a smear evocative of a high-grade
lesion at the first examination with a high-risk HPV (100%). This
diagnosis was confirmed by the biopsy in these 25 patients. Fifty-
six women had a smear evocative of low-grade lesions at the first
examination with 43 high-risk HPV (76.8%) and four low-risk
HPV (7.1%). The final histological diagnosis was a low-grade
lesion in 42 cases and a high-grade lesion in two women. Twelve
women did not present any cytological and histological lesion at
the second control 40–120 days later. The absence of lesions was
associated with the regression of HPV infection in seven of these
cases (six high-grade and one low-grade) without any treatment
and two persistent high-risk HPV infection.
Twenty-three women (1.5%) presented ASCUS. High-risk HPV
DNA was present in 11 cases (47.8%). At the second control, one
ASCUS corresponded to a high-grade lesion, five to a low-grade
lesion and all these lesions were associated with high-grade HPV.
The other 17 women did not present any detectable lesion at the
colposcopy and/or the biopsy, but there was a persistent high-risk
HPV infection in one case. At the third control, a high-grade lesion
was detected in this woman.
In the remaining population of 1414 women with cervical smears
within normal limits, high-risk HPV DNA was detected in 168
women (11.9%) and low-risk HPV in 85 cases (6.0%). In this popu-
lation, 61 women with initial HPV infection had a follow-up: 42
with a high-risk HPV and 19 with a low-risk HPV. A persistent high-
risk HPV infection at the second examination was observed in 26
out of 42 women and was associated with the detection of a high-
grade lesion in five patients, 3–15 months after the first entry, and
the detection of a low-grade lesion in five other women 4–10 months
after the first examination. Three women with a high-risk HPV
infection at the first examination had a low-risk HPV infection at the
Table 2 Follow-up from the first smear to the final diagnosis
Cytology Histology
First smear HPV Final histological diagnosis HPV
HR LR HR LR
1414 WL 168 85 5 HG-SIL 5 0
7 LG-SIL 7 0
23 ASCUS 11 0 2 HG-SIL 2 0
5 LG-SIL 5 0
56 LG 43 4 2 HG-SIL 2 0
42 LG-SIL 35 3
25 HG 25 0 25 HG-SIL 25 0
WL: without lesion; LG: low-grade lesion; HG: high-grade lesion; HR: high-risk HPV; LR: low-risk HPV.
Table 3 Evaluation of cytology and high-risk HPV testing for the detection of a histologically proven high-grade lesion
Methods Sensitivity Specificity PPV
Cytology 29/34 (85.3%) 1409/1984 (94.9%) 29/104 (27.9%)
HPV detection 34/34 (100%) 1265/1484 (85.2%) 34/253 (13.4%)
High-risk HPV DNA level
in conizations (ratio)
>50 68.0% 71.4% 92.7%
>100 56.0% 78.6% 93.3%
>200 46.7% 85.7% 94.6%
>500 24.0% 92.8% 94.7%
PPV: predictive positive value.second examination. A persistent low-risk HPV infection at the
second examination was observed in eight out of 19 women and was
associated with the detection of three low-grade lesions, within 4–12
months. Moreover, five other women of this group were secondly
infected with high-risk HPV and developed three low-grade lesions
within 6–14 months.
Thus in our series, 34 patients had a final diagnosis of high-
grade lesion at the biopsy. All these women (100%) had previous
scrapes positive for high-risk HPV. Earlier classic cytological
screening revealed the absence of lesion in five cases (14.7%), the
presence of ASCUS in two cases (5.9%) and cytological abnor-
malities evocative of low-grade lesion in two cases (5.9%) and of
high-grade lesion in 25 cases (73.5%). In the 58 low-grade lesions,
high-risk HPV were detected in 47 women (81.0%) and low-risk
HPV in seven cases (12.1%).
Pilot study: HPV testing on cone biopsy samples
On the 117 cone biopsies, the cervical scrapes performed on fresh
tissue revealed the presence of high-risk HPV in 89 cases (76.1%).
Seven of 20 inflammatory lesions (35.0%), seven of ten low-grade
lesions (70.0%), 68 of 70 high-grade lesions (97.1%) and the seven
invasive carcinomas (100%) were positive. The entire cone biopsy
samples were histologically examined and so the final diagnosis
was definitive. The absence of SIL in the 20 inflammatory lesions
may be explained by excision-treatment with the biopsy or a spon-
taneous regression of the lesion.
Evaluation of the viral load as a predictive parameter
Considering the viral load appreciated by the HC-II test, women
with high-grade lesions had significantly higher signal strengths
for high-risk HPVs than the rest of the population (Kruskal–Wallis
test; P < 10–8). In the same way, there was a significant difference
in the viral load at the first examination for the 13 women with
normal smears and a regressive high-risk HPV infection (mean
signal strength of 74 units) and the 26 women with normal smears
and a persisting high-risk HPV infection (mean signal strength of
190 units) especially when this infection was associated with the
apparition of cervical lesions (mean signal strength of 320 units)
(P < 0.01).
With a view to clinical application, we chose to test the sensi-
tivity and specificity of the high-risk HPV DNA level for the
detection of histologically proven high-grade lesions on our cone
biopsy samples showing high-grade SIL and in samples obtained
from 25 women without any CIN at the biopsy. The results
obtained are summarized in Table 3.
Table 3 represents the respective sensitivity, specificity and
positive predictive values of the various methods used for the
detection of a high-grade SIL histologically proven.
DISCUSSION
This work using the HC-II assay on a series of 1518 unselected
women attending routine cytological screening clearly underlines
the significant prevalence and/or persistence of HPV infection in
women presenting precancerous and malignant cervical lesions.
Also, there is a significantly increased prevalence of HPV detec-
tion, especially high-risk HPV, related to the severity of the lesion.
Moreover, the prevalence of HPV infection is higher in women
with a history of low- and/or high-grade lesions in a previous
cervical smear or biopsy. HPV DNA has been detected in 400
(24.3%) of 1647 scrapes, with 296 (18.0%) containing a high-risk
HPV. High-risk HPV was detected in all 34 cases presenting a
high-grade lesion confirmed by biopsy, and in 68 (97.1%) of the 70
cone biopsy samples showing a high-grade SIL or an invasive
carcinoma. Thus, the overall sensitivity of HC-II in detecting high-
grade SILs and cervical cancers is 98.1%, and the specificity is
85.2% in cervical scrapes. The sensitivity of HC-II is quite similar
to that of PCR using ‘consensus’ primers in previous studies (Van
den Brule et al, 1991; Bosch et al, 1995). These data confirm our
preliminary results comparing the respective sensitivities of HC-I,
HC-II and PCR on 44 cone biopsy samples (Clavel et al, 1998b).
Besides, in our experience, classic cytological screening gave posi-
tive results in 85.3% of the 34 high-grade lesions proven by the
biopsy and its specificity was 94.9%. Thus even if it is less
specific, HC-II represents a more sensitive test than classic
cytology for the detection of high-grade cervical lesions.
In another way, we found 168 women (11.9%) infected with
high-risk HPV positivities in a population of 1414 women with
smears without any cytological abnormalities. The prevalence of
HPV infection in our population is higher than that previously
reported by other authors with the use of PCR (Walboomers et al,
1994; Rozendaal et al, 1996) and may be explained by our hospital
recruitment with a subpopulation of women at high-risk. However,
Rozendaal et al (1996) emphasized that the women with normal
smears and high-risk HPV genotypes were 116 times more at risk
of developing high-grade SIL, in contrast to women without high-
risk HPV. Nevertheless the significance of such positivities and
their predictive value are not totally resolved at the present time.
Many HPV infections are known to regress spontaneously. In
another way, in the literature, the persistence of high-risk HPV is
significantly associated with progressive disease (Ho et al, 1995;
Remmink et al, 1995). Our preliminary results on the follow-up of
61 women with HPV infection and smears within normal limits
show that persistent HPV infection at a second examination in 42
cases was associated with the discovery of low-grade lesions in 11
cases and high-grade lesions in five cases within 3–15 months. The
different modalities of collection of the samples may explain false-
negative results of the cytology at the first entry. Cytology samples
collected with Ayre’s spatula remove cells from the ectocervix and
part of the transformation zone, whereas the cytobrush predomi-
nantly samples the endocervical canal as well as higher parts of the
transformation zone. So these two different methods for collecting
provide complementary data. Another source of cytological false-
negative results is the rapid development of the lesions. Whatever
the explanation of these apparently discrepant results, a more
intensive cytological screening with HPV testing and clinical
management with colposcopy should be offered in such high-risk
HPV positive women without cytologic abnormalities, with an
algorithm of 6 months to 1 year, to confirm the persistence of HPV
infection and/or the occurrence of SIL.
Cuzick et al (1994) showed that in women with cytological
abnormalities, HPV positivity at a high level detected by a semi-
quantitative PCR was strongly related to high-grade CIN. Ho et al
(1995) have also suggested that SIL with a high viral load are more
likely to persist than those with a low level of HPV DNA. Thus, a
high viral load may be considered as a risk factor and preferentially
observed in potentially evolutive and in high-grade lesions. This
parameter could be semi-quantitatively evaluated by the relative
Routine HPV screening with Hybrid Capture II 1309
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the quantitative approach provided by the HC-I assay for the
assessment of the viral load could not clearly distinguish between
cases with or without high-grade lesions. Our present results with
HC-II show that there is a highly significant correlation between a
high level of high-risk HPV DNA and the severity of lesions.
Moreover, a high viral load at a first examination is significantly
associated with the persistence of viral infection or the apparition of
a high-grade lesion in our series of 42 women followed up with a
normal smear and a high-risk HPV infection. But, when this para-
meter is basically applied to differentiate patients with histologi-
cally proven high-grade SIL from women without any detectable
lesions, it does not provide reliable sensitivity and specificity.
Indeed, for a cervical sample/positive control ratio > 200, indi-
cating a high viral load, the sensitivity is only 46.7% and the speci-
ficity 85.7%. However, we cannot exclude the possibility that
women without cytological abnormal lesions, but with a high level
of oncogenic HPV DNA, may represent a population at risk for the
development of high-grade SIL or patients with an undetected SIL.
Besides one major bias of this parameter evaluation remains the
cell number in the cervical swabs which is not quantitated and can
vary from one sample to another. In our experience at the present
time, high-risk HPV DNA quantitation by HC-II cannot be consid-
ered a relevant test to be used in practice for the detection of high-
grade lesions.
In conclusion, HPV detection with the HC-II assay represents a
convenient and easy test for routine use. In our experience, its
sensitivity for the detection of high-grade cervical lesions is higher
than classic cytological screening, 98.1% versus 85.3% for
cytology. This high sensitivity makes this assay highly recom-
mendable for routine screening of high-grade lesions, in associa-
tion with cytological examination. With the combination of the
two methods, high-grade lesions would not be missed. The prog-
nostic significance of a high level of high-risk HPV DNA detected
with this assay has to be evaluated with repeat tests and follow-up
of a large cohort of women. In a recent paper, Wright et al (1998)
recommended the use of this test for older women (> 30 years old)
and women with ASCUS. This would indeed improve the positive
predictive value of the test. In our study, the application of this
schedule of screening would increase the positive predictive value
from 13.4% to 18.8%. However, considering the increasing occur-
rence of high-grade SIL in women under this age (nine cases out of
34 in our series of high-grade SIL), we propose to extend this indi-
cation to all women. At the present time, the cost of a HC-II test is
about UK£25. Thus this proposition has to be evaluated in terms of
cost-benefits in screening programmes.
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